NEW YORK – Immunocore said on Friday that it plans to submit a biologic license application to the US Food and Drug Administration in Q3 2021 for tebentafusp to treat HLA-A*02:01-positive patients with metastatic uveal melanoma.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.